Program
bexobrutideg
Its studies are mostly in Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell, led by Nurix Therapeutics.
Furthest: phase 3, since Mar 31, 20266 company-led studies, 4 open or runningNext primary completion: Jan 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nurix Therapeutics | 64 open or running | phase 3since Mar 31, 2026 | Nov 12, 2021 | Jan 2027phase 1 · NCT05131022 |
- Named in hoffmann la roche’s own pipeline as
RG7473 bexobrutideg (Nurix)
, phase 3, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2021First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT05131022 · 572 planned · United States, France, Italy and more
- Nov 1, 2024Phase 1 study in Healthy VolunteerNCT06691828 · 8 enrolled · United States
- Dec 1, 2024Phase 1 study in Healthy VolunteerNCT06717269 · 223 enrolled · United States
- Oct 24, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07221500 · 100 planned · United States, France, Italy and more
- Mar 31, 2026Phase 3 study in Lymphoma, B-CellPhase 3 reachedNCT07516093 · 620 planned · United States
- Apr 2, 2026Phase 2 study in Lymphoma, B-CellNCT07520006 · 150 planned · United States
Ahead
- Jan 2027Primary completion: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05131022
- Jan 2028Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07221500
- Oct 2029Primary completion: phase 3 study in Lymphoma, B-CellNCT07516093
- May 2033Primary completion: phase 2 study in Lymphoma, B-CellNCT07520006
TargetBeta
“An orally bioavailable chimeric targeting molecule (CTM) and targeted degrader of Bruton's tyrosine kinase (BTK), ”NCIt, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07520006Lymphoma, B-Cell · United States | 2 | Recruiting | May 2033 | 150 |
| NCT07516093Lymphoma, B-Cell · United States | 3 | Recruiting | Oct 2029 | 620 |
| NCT07221500Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Italy and more | 2 | Recruiting | Jan 2028 | 100 |
| NCT06717269Healthy Volunteer · United States | 1 | Completed | May 1, 2026 | 223 |
| NCT06691828Healthy Volunteer · United States | 1 | Completed | Nov 28, 2024 | 8 |
| NCT05131022Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Italy and more | 1 | Recruiting | Jan 2027 | 572 |
How it is read
Names in the registry
- “NX-5948”, 7 entries
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 2 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.